Nasdaq · Healthcare
Kiniksa Pharmaceuticals International, plc (KNSA)
As-reported financials and recent SEC filings for Kiniksa Pharmaceuticals International, plc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$677.6M
Net income
$59.0M
Net margin
8.7%
Diluted EPS
$0.75
ROE
10.4%
P/E (TTM)
65.1×
Market cap
$4.55B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $677.6M | $423.2M | $270.3M | $220.2M | $38.5M |
| Gross profit | $599.9M | $362.3M | $236.9M | $197.3M | $29.4M |
| Operating income | $77.2M | $-45.6M | $-25.2M | $9.8M | $-156.6M |
| Net income | $59.0M | $-43.2M | $14.1M | $183.4M | $-157.9M |
| Diluted EPS | $0.75 | $-0.60 | $0.20 | $2.60 | $-2.30 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →Go deeper on KNSA
Search Kiniksa Pharmaceuticals International, plc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.